Poseida postpones IPO in favor of $142M series C

Poseida raised a $142 million series C round Monday that includes a $75 million contribution from Novartis AG (NYSE:NVS; SIX:NOVN).

CEO Eric Ostertag told BioCentury that Poseida Therapeutics Inc. (San Diego, Calif.) has withdrawn the IPO prospectus it filed in January, but still may opt to refile for an IPO in late 2019 or early 2020 (see "Poseida's Sea Change")...